Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

NCT00670488 | Completed Phase 1 Results

• 3 other identifiers: 2206-0022008_513MK-2206-002
• Study Type: interventional
• Target: 104
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary purpose of this study is to investigate the Dose Limiting Toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2206 administered orally to participants with advanced solid tumors. The preliminary efficacy of MK-2206 will also be investigated.

Conditions

Locally Advanced Tumors; Metastatic Solid Tumors; Cancer; Neoplasms

Outcome Measures

Primary Outcomes (12)

• Number of Participants With Dose Limiting Toxicities (DLTs)

  DLT was any drug-related AE, regardless of grade, leading to a dose modification of MK-2206. Dose-limiting hematologic and nonhematologic toxicities were defined differently and were based on events occurring during the first cycle of study drug administration. Hematologic DLT defined as any Grade (Gr) 4 or greater hematologic toxicity except neutropenia described as follows: Neutropenia that was Gr 4 lasting for ≥7 days, or Gr 3/Gr 4 with fever \>38.5°C and/or infection requiring antibiotic or anti-fungal treatment considered DLT. Gr 4 thrombocytopenia (≤25.0 x 10\^9/L) was also considered DLT. Non-hematologic DLTs were defined as any Gr 3, 4, or 5 nonhematologic toxicity, with the specific exceptions of: Gr 3 nausea, vomiting, diarrhea, or dehydration occurring with inadequate supportive care and lasting \<48 hours; alopecia; inadequately treated hypersensitivity reactions; and Gr 3 elevated transaminases of ≤1 week in duration. A participant could have more than one DLT.

  Day 1 to Day 28 (Cycle 1)

• Number of Participants With One or More Adverse Events (AE)

  An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which was temporally associated with the use of the SPONSOR's product, was also an AE. The number of participants that experienced one or more AEs was reported for each dose level group.

  Up to 269 days

• Area Under the Concentration-time Curve of MK-2206 From Time 0 to 48 Hours (AUC0-48hr) in Participants Receiving Multiple QOD Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. AUC 0-48hr was calculated for Day 1 and the last day of treatment in Cycle 1 (Day 27) and reported for all dose levels receiving MK-2206 orally QOD (30, 60, 75, and 90 mg QOD).

  Days 1 and 27: predose and 0.5, 1, 2, 3, 4, 6, 10, 24, and 48 hours after MK-2206 dosing

• Maximum Concentration (Cmax) of MK-2206 in Participants Receiving Multiple QOD Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. Cmax was calculated for Day 1 and the last day of treatment in Cycle 1 (Day 27) and reported for all dose levels receiving MK-2206 orally QOD (30, 60, 75, and 90 mg QOD).

  Days 1 and 27: predose and 0.5, 1, 2, 3, 4, 6, 10, 24, and 48 hours after MK-2206 dosing

• Concentration of MK-2206 After 48 Hours (C48hr) in Participants Receiving Multiple QOD Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. C48hr was calculated for Day 1 and the last day of treatment in Cycle 1 (Day 27) and reported for all dose levels receiving MK-2206 orally QOD (30, 60, 75, and 90 mg QOD).

  Days 1 and 27: predose and 48 hours after MK-2206 dosing.

• Time to Maximum Concentration (Tmax) of MK-2206 in Participants Receiving Multiple QOD Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. Tmax was calculated for Day 1 and the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QOD (30, 60, 75, and 90 mg QOD).

  Days 1 and 27: predose and 0.5, 1, 2, 3, 4, 6, 10, 24, and 48 hours after MK-2206 dosing

• Apparent Terminal Half-life (t½) of MK-2206 in Participants Receiving Multiple QOD Dosing

  Blood samples were collected for PK analyses on Day 27 of the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. t½ (Harmonic mean ± pseudo SD) was calculated and reported for all dose levels receiving MK-2206 orally QOD (30, 60, 75, and 90 mg QOD).

  Day 27: predose and 0.5, 1, 2, 3, 4, 6, 10, 24, and 48 hours after MK-2206 dosing.

• AUC0-168hr in Participants Receiving Multiple QW Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. AUC 0-168 was calculated for Day 1 and the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QW (90, 135, 200, 300, 250, and 150 mg QW).

  Days 1 and 22: predose and 2, 4, 6, 10, 24, 48, 96 hours, and 168 hours after MK-2206 dosing

• Cmax of MK-2206 in Participants Receiving Multiple QW Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. Cmax was calculated for Day 1 and the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QW (90, 135, 200, 300, 250, and 150 mg QW).

  Days 1 and 22: predose and 2, 4, 6, 10, 24, 48, 96 hours, and 168 hours after MK-2206 dosing

• C48hr of MK-2206 in Participants Receiving Multiple QW Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. C48hr was calculated for Day 1 and the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QW (90, 135, 200, 300, 250, and 150 mg QW).

  Days 1 and 22: predose and 48 hours after MK-2206 dosing

• Tmax of MK-2206 in Participants Receiving Multiple QW Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. Tmax was calculated for Day 1 and the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QW (90, 135, 200, 300, 250, and 150 mg QW).

  Days 1 and 22: predose and 2, 4, 6, 10, 24, 48, 96 hours, and 168 hours after MK-2206 dosing

• t½ of MK-2206 in Participants Receiving Multiple QW Dosing

  Blood samples were collected for PK analyses during the first cycle of therapy. Samples were centrifuged, plasma was withdrawn and plasma concentrations were analyzed by high performance liquid chromatography with tandem mass spectroscopy. t½ (Harmonic mean ± pseudo SD) was calculated for the last day of treatment in Cycle 1 and reported for all dose levels receiving MK-2206 orally QW (90, 135, 200, 300, 250, and 150 mg QW).

  Day 22: predose and 2, 4, 6, 10, 24, 48, 96 hours, and 168 hours after MK-2206 dosing

Secondary Outcomes (2)

• Phosphorylated Protein Kinase B (pAkt) Level on Cycle 1 Day 15 (C1D15) After Treatment With MK-2206 at the Maximum Tolerated Dose (MTD)

  Baseline, Cycle 1 Day 15

• Number of Participants With Confirmed Response as Per Response Evaluation Criteria in Solid Tumors (RECIST)

  From Cycle 1 Day 1 through the End of Study Visit (up to 6 months)

Study Arms (10)

MK-2206 30 mg QOD

EXPERIMENTAL

Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 60 mg QOD

EXPERIMENTAL

Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 75 mg QOD

EXPERIMENTAL

Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 90 mg QOD

EXPERIMENTAL

Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 90 mg QW

EXPERIMENTAL

Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 135 mg QW

EXPERIMENTAL

Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 200 mg QW

EXPERIMENTAL

Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 300 mg QW

EXPERIMENTAL

Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 250 mg QW

EXPERIMENTAL

Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Drug: MK-2206

MK-2206 150 mg QW

EXPERIMENTAL

Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Drug: MK-2206

Interventions

MK-2206 DRUG

MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

MK-2206 135 mg QW; MK-2206 150 mg QW; MK-2206 200 mg QW; MK-2206 250 mg QW; MK-2206 30 mg QOD; MK-2206 300 mg QW; MK-2206 60 mg QOD; MK-2206 75 mg QOD; MK-2206 90 mg QOD; MK-2206 90 mg QW

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy
• Has normal organ function; is no greater than 2 on the ECOG Performance Scale
• Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if participant is female
• Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis

You may not qualify if:

• Participant has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment
• Is currently participating or has participated in a study with an investigational compound or device within 30 days
• Has a primary central nervous system tumor
• Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure
• Is a known diabetic who is taking insulin or oral antidiabetic therapy
• Is pregnant or breastfeeding or planning to become pregnant during the study
• Is HIV-positive
• Has known history of Hepatitis B or C or active Hepatitis A
• Is receiving treatment with oral corticosteroids

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (2)

• Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.

  PMID: 22025163 RESULT

• Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078-0432.CCR-14-0868. Epub 2014 Sep 19.

  PMID: 25239610 DERIVED

MeSH Terms

Conditions

Neoplasms

Interventions

MK 2206

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Monitor

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2008
• First Posted: May 1, 2008
• Study Start: April 15, 2008
• Primary Completion: July 11, 2011
• Study Completion: July 11, 2011
• Last Updated: April 1, 2019
• Results First Posted: April 1, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will share